Our research work has led to the creation of start-ups, online tools, and the filing of several patents.
Creation of economic activity
| Optim’care | Assistance in the creation of Optim’Care (2018), a spin-off of UMR1248 aimed at promoting the results of its research. Optim’Care, chaired by Mrs. Julie Vandenbergue, developed digital tools for optimized and personalized care of transplant patients. It was acquired in December 2022 by SEMEIA and integrated into its telehealth platform. | |
 |
Online Tools
 |
||
Patents
Accepted patents
“Methods for predicting graft failure risk”. Application claiming priority of European patent application EP17305611.0, déposée le 24/05/2017
“Biomarkers for typing allograft recipients”. Application claiming priority of European patent application No. 17306944.4, déposée le 27/12/2017
Method for the treatment of heart disease in mammals (PCT/EP2018/059295, filed on 11 April 2018). Applicant CEVA SANTE ANIMALE, Libourne, France.
Methods and pharmaceutical composition for the treatment of hidradenitis suppurativa in patients in need thereof. PCT/FR2018/052164 filed on 5 September 2018. Applicant INSERM, Limoges, France.
Methods and kits for detecting liver dysfunction in a subject (EP18306528.3, 20 November 2018) PCT/EP2019/081801, filed on 19 November 2019. Applicant INSERM, Limoges, France.
mRNA-based biomarkers for antibody-mediated transplant rejection (ZL917195 – EP19152365.3, filed on 17 January 2019). Applicant KATHOLIEKE UNIVERSITEIT LEUVEN, Belgium
“Method for assessing the area under the curve of an immunosuppressant and associated method and systems”. Brevet EP20306278.1 déposé le 26/10/2020
“Use of albumin isoforms profiles for the characterization of the etiology and severity of liver injuries”. Application claiming priority of European patent application EP22306513.7, déposée le 07/10/2022
“Computer-implemented diagnostic method for determining the clinical interpretation of renal graft alterations”. Application claiming priority of European patent application PCT/EP2022/061297, déposée le 28/04/2022. Application to USPTO (United States Patent and Trademark Office) déposée le 26/10/2023.
Filed patents
« Modèle de machine learning pour prédire l’exposition au mycophenolate mofetil ». N° de dépôt IDDN.FR.001.040010.000.S.P.2025.000.31230, déposé le 21/01/2025 « Modèle de machine learning pour prédire l’exposition à la cyclosporine ». N° de dépôt IDDN.FR.001.040010.000.S.P.2025.000.31230, déposé le 21/01/2025 « Modèle de machine learning pour prédire l’exposition au tacrolims ». N° de dépôt IDDN.FR.001.040010.000.S.P.2025.000.31230, déposé le 21/01/2025